They also had lower median PSA levels at baseline, lower median Gleason scores, lower percentages of stage M1c cancer at the time of initial docetaxel treatment and at the index date, fewer median cycles of initial docetaxel treatment, and fewer systemic therapies between mCRPC diagnosis and index date and between initial docetaxel rechallenge and index date. This evidence concerns the gene KLK3 and cancer.